ThinkEquity Initiates Coverage on Gen-Probe (GPRO) with a Buy
ThinkEquity initiates coverage on Gen-Probe (Nasdaq: GPRO) with a Buy rating. Price target $55.
To see more analyst ratings on GRPO Click Here.
Gen-Probe Incorporated (Gen-Probe) is engaged in the development, manufacture and marketing of nucleic acid probe-based products used for the clinical diagnosis of human diseases and for screening donated human blood.
Related Categories
New CoverageStocks Mentioned
Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
